1,721,716 research outputs found
Telegram from Jerry to Reverend John Cunningham
Full text linkWestern Union Telegram from Jerry to Reverend John Cunningham from Middletown, NJ, October 4, 1974https://digitalcommons.providence.edu/fantasticks_1975_commentary/1000/thumbnail.jp
John Cunningham, National Society of Pershing Rifles
No full textJohn Cunningham was a student at Jacksonville State College (now Jacksonville State University) in the mid 1960s. In 1965 he was a cadet in the National Society of Pershing Rifles.https://digitalcommons.jsu.edu/lib-ac-histimg/13481/thumbnail.jp
John Cunningham Virus
No full textThis learning object is a narrated Power Point presentation describing the features of, risk factors for, and clinical presentations of the John Cunningham, or JC, virus. It includes a discussion of various immunosuppressed states, including HIV, use of natalizumab (a disease-modifying therapy that is used to treat patients with multiple sclerosis), and others, that may predispose to the development of progressive multifocal leukoencephalopathy (PML), the clinical neurologic syndrome of the JC virus. Neuro-ophthalmic features of PML, which may include homonymous hemianopia, disorders of higher cortical processing of visual stimuli, cortical blindness, and ocular motility abnormalities, are emphasized
Reverend John Cunningham and his day scholar academics.
No full textGroup portrait of Reverend Father John Cunningham S.J. with his Day Scholar Academics. Taken outdoors in garden in front of ivy-covered adobe wall
Reverend John Cunningham and his day scholar academics.
No full textGroup portrait of Reverend Father John Cunningham S.J. with his Day Scholar Academics. Taken outdoors in garden in front of ivy-covered adobe wall
Structural vaccinology, molecular simulation and immune simulation approaches to design multi-epitopes vaccine against John Cunningham virus
Full text linkThe JCV (John Cunningham Virus) is known to cause progressive multifocal leukoencephalopathy, a condition that results in the formation of tumors. Symptoms of this condition such as sensory defects, cognitive dysfunction, muscle weakness, homonosapobia, difficulties with coordination, and aphasia. To date, there is no specific and effective treatment to completely cure or prevent John Cunningham polyomavirus infections. Since the best way to control the disease is vaccination. In this study, the immunoinformatic tools were used to predict the high immunogenic and non-allergenic B cells, helper T cells (HTL), and cytotoxic T cells (CTL) epitopes from capsid, major capsid, and T antigen proteins of JC virus to design the highly efficient subunit vaccines. The specific immunogenic linkers were used to link together the predicted epitopes and subjected to 3D modeling by using the Robetta server. MD simulation was used to confirm that the newly constructed vaccines are stable and properly fold. Additionally, the molecular docking approach revealed that the vaccines have a strong binding affinity with human TLR-7. The codon adaptation index (CAI) and GC content values verified that the constructed vaccines would be highly expressed in E. coli pET28a (+) plasmid. The immune simulation analysis indicated that the human immune system would have a strong response to the vaccines, with a high titer of IgM and IgG antibodies being produced. In conclusion, this study will provide a pre-clinical concept to construct an effective, highly antigenic, non-allergenic, and thermostable vaccine to combat the infection of the John Cunningham virus
John Cunningham Virus seroconversion during natalizumab treatment
Full text linkIntroduction: Multiple sclerosis is a progressive disease that is difficult to predict, originating in cases of disability. Natalizumab is a highly effective disease-modifying therapy but is associated with greater John Cunningham virus (JCV) reactivation and consequent increased risk of developing Progressive Multifocal Leukoencephalopathy (PML). Objective: To analyze JCV seroconversion in patients treated with natalizumab. Methods: A retrospective study was conducted involving patients diagnosed with multiple sclerosis, between January 2012 and December 2021. To assess seroconversion during treatment with natalizumab, patients were considered seronegative at the beginning of treatment and who had at least one result in the period of medication use. The study was approved by the Human Research Ethics Committee under protocol 3,177,442. Results: Sixty-two patients treated with Natalizumab were included, with a seroprevalence of 67.7%. At the start of treatment, 41.9% (26/62) of the patients were negative for anti-JCV, of which 23.1% (6/26) were seroconverted. The mean time to seroconversion was 2.5 years. The baseline index of anti-JCV antibodies was statistically significant with the age of the patients. Among patients with a negative anti-JCV antibody result at baseline, 82.6% (19/23) remained negative throughout monitoring. Treatment was discontinued in 53.2% (33/62) of patients, and 72.7% (24/33) due to anti-JCV positivity with a consumption index >1.5 in 41.9% of cases. Conclusion: Knowing how to monitor the anti-JCV antibody index and treatment approaches in our patient cohort may be useful in future clinical decisions in treating MS
- …
